Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

454
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
454
Cancer Vaccines01:30

Cancer Vaccines

313
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
313
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

5.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Blood Rheology After Allogeneic Hematopoietic Stem Cell Transplantation or Gene Therapy in Sickle Cell Disease.

Blood advances·2026
Same author

SGK1-mediated deficits in microglial phagocytosis drive pathological progression in amyotrophic lateral sclerosis.

Journal of neuroinflammation·2026
Same author

A prognostic senescence-related long non-coding RNA signature identifies cold and hot tumors of stomach adenocarcinoma.

Oncology letters·2026
Same author

A portable non-contact tongue imaging system with automated analysis for community and home settings.

Digital health·2026
Same author

Donor lymphocyte infusions after HCT are associated with low risk of graft-versus-host disease in pediatric and young adult patients.

Blood immunology & cellular therapy·2026
Same author

Author Correction: cBAF complex components and MYC cooperate early in CD8<sup>+</sup> T cell fate.

Nature·2026

相关实验视频

Updated: May 21, 2025

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.1K

在癌症治疗中,VDAC2损失引起瘤破坏和炎症.

Sujing Yuan1, Renqiang Sun1, Hao Shi1

  • 1Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Nature
|March 20, 2025
PubMed
概括

瘤细胞通过涉及电压依赖的离子通道2 (VDAC2) 的机制逃避免疫攻击. 通过使干扰素 (IFNγ) 触发细胞死亡和先天免疫反应,向VDAC2可增强抗瘤免疫力和免疫疗法的有效性.

更多相关视频

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.5K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.3K

相关实验视频

Last Updated: May 21, 2025

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.1K
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.5K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.3K

科学领域:

  • 免疫学
  • 分子生物学
  • 癌症研究

背景情况:

  • 瘤细胞经常躲避免疫监测和治疗干预,其潜在机制在很大程度上是未知的.
  • 在癌症治疗中,CD8+ T细胞和免疫疗法耐药性构成重大挑战.
  • 了解瘤免疫规避对于开发有效的癌症疗法至关重要.

研究的目的:

  • 为了识别新的分子点,
  • 研究新陈代谢因素对瘤抵抗免疫攻击的作用.
  • 探索VDAC2作为增强抗瘤免疫力和免疫治疗的潜在目标.

主要方法:

  • 在体内和体外的CRISPR-Cas9基因选以准代谢因素.
  • 基因组规模的基因相互作用屏幕来识别相互作用的基因.
  • 对干扰素- (IFNγ) 信号通路和线粒体损伤的分析.
  • 对cGAS-STING激活和I型IFN反应进行评估.

主要成果:

  • 确定了电压依赖的离子通道2 (VDAC2) 作为一个依赖免疫信号的检查点,限制了IFNγ介导的瘤破坏.
  • 在瘤细胞中准VDAC2增强了IFNγ诱导的细胞死亡,cGAS- STING激活和抗瘤反应.
  • BAK被确定为VDAC2缺陷诱导作用的关键媒介,导致不受控制的BAK激活和线粒体损伤.
  • 线粒体DNA的异常释放触发了cGAS-STING信号和I型IFN反应,增强了抗瘤免疫力.

结论:

  • 通过增强适应性和先天性免疫反应,VDAC2是克服瘤免疫逃避的关键目标.
  • 向VDAC2促进瘤细胞死亡和炎症,提高癌症免疫疗法的疗效.
  • 协调的瘤破坏和炎症对于成功的癌症免疫疗法至关重要.